Quantcast

Latest Monoclonal antibodies Stories

2014-06-11 23:13:29

New England Peptide and SISCAPA expand commercialization of mass spec biomarker assays. Gardner, MA (PRWEB) June 11, 2014 Today, New England Peptide, Inc. (NEP) and SISCAPA Assay Technologies, Inc. (SAT) announced a collaboration for the manufacture and sale of Stable Isotope Standard (SIS) peptides for use in SISCAPA® protein quantification assays. Under the terms of the agreement, NEP will manufacture peptide standards suitable for use with SAT’s SISCAPA assays. The peptides will...

2014-06-11 08:29:19

LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ -- RuiYi, Inc., a global therapeutic innovation leader, announced today the close of a $4 million debt financing from Silicon Valley Bank to advance a pipeline of novel monoclonal antibodies (mAb) targeting G protein coupled receptors (GPCRs). RuiYi plans to file an IND and initiate clinical trials in multiple countries in 2015 for the company's lead asset, RYI-008, a novel anti-IL-6 mAb for rheumatoid arthritis and cancer....

2014-06-11 08:29:17

New antibodies generated with RuiYi's iCAPS technology to explore GPCR structure and function LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ -- RuiYi, a global therapeutic innovation leader, and iHuman Institute at ShanghaiTech University announced today a new research collaboration applying RuiYi's iCAPS (Intermembranous Conformation Antigen Presenting System) technology to create novel monoclonal antibodies with specific binding to G protein coupled receptors (GPCRs) to...

2014-06-11 04:21:56

- Findings Show Positive Association Between Adherence and Anti-TNF Therapy Compared to Conventional Therapy PARIS, June 11, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were...

2014-06-10 16:27:52

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Antibody Partnering Terms and Agreementshttp://www.reportbuyer.com/countries/north_america/usa/antibody_partnering_terms_agreements.html The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.The Antibody Partnering Terms and...

2014-06-06 08:24:52

Initial clinical experience with 89Zr-labeled anti-PSMA minibody presented LOS ANGELES, June 6, 2014 /PRNewswire/ -- ImaginAb, Inc., in collaboration with Memorial Sloan-Kettering Cancer Center (MKSCC), will be presenting initial clinical data with an anti-PSMA recombinant antibody fragment (a "minibody") derived from the huJ591 monoclonal antibody, in patients with metastatic prostate cancer. The presentation of this initial data coincides with the Company's preparation to expand...

2014-06-05 23:12:01

ResearchMoz.us includes new market research report "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports. Albany,New York (PRWEB) June 05, 2014 Researchmoz presents this most up-to-date research on "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation". The report focuses primarily on quantitative market metrics in order to characterize the growth and...

2014-06-05 23:09:14

Selexis to Meet with Biopharmaceutical Companies Interested in Protein Drug Discovery, Mammalian Cell Line Development and Lead Identification for Therapeutic Drug Development and Manufacturing Geneva, Switzerland (PRWEB) June 05, 2014 Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development, announced today that representatives from the Company will be participating in the BIO International Convention’s One-on-One...

2014-06-05 12:31:16

MELBOURNE, Australia, June 5, 2014 /PRNewswire/ -- Nexvet Biopharma, a leading veterinary biologic drug developer, today announced the oral presentation of data related to clinical development of NV-01, a novel canine monoclonal antibody (mAb) at a major upcoming veterinary meeting, the publication of a further peer-reviewed journal article regarding NV-01, and Nexvet's sponsorship of a pain management specialist veterinary meeting. 1. NC State Clinician Scientist Duncan Lascelles, BSc,...

2014-06-04 08:29:36

MUMBAI and LA CHAUX-DE-FONDS, Switzerland, June 4, 2014 /PRNewswire/ -- - State-of-the-art Manufacturing Facility for Supply of Clinical Trial Material - With the Facility Glenmark has end-to-end Capabilities for the Development of Novel, State-of-the-art Monoclonal Antibodies Including Bi-specific Antibodies Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, India (GPL), announced the opening of its new cGMP...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related